MRNA vs PROK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

MRNA

41.2
AI Score
VS
PROK Wins

PROK

67.9
AI Score

Investment Advisor Scores

MRNA

41score
Recommendation
HOLD

PROK

68score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA PROK Winner
Net Income -2.82B -48.46M PROK
Operating Income -3.07B -93.31M PROK
ROE -32.6% 5.5% PROK
ROA -22.9% -19.5% PROK
Total Assets 12.34B 249.02M MRNA
Cash 2.60B 74.87M MRNA
Current Ratio 3.29 8.36 PROK
Free Cash Flow -2.06B -89.68M PROK

Relative Price Performance (Last 90 Days)

MRNA 1M: +2.7% · 3M: +259.7% PROK 1M: -16.1% · 3M: -8.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (55.4% over 20 days), RSI 50

RSI (14): 50.2 · Price: $200.10

PROK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.4%), weak momentum, RSI 39

RSI (14): 38.9 · Price: $1.41

Fundamentals Snapshot

Metric MRNA PROK
Market Cap — —
Forward P/E -41.9 -2.3
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% -0.3%
Gross Margin -0.7% 1.0%
Operating Margin -5.6% -322.5%
EPS -6.58 -0.55
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PROK is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.